CureMetrix
An EvoNexus Incubator Company
CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. We are focused on developing the next generation of medical image analysis technology that healthcare providers and patients can confidently rely on.
Using our patent-pending algorithm, we are developing an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their breast cancer screening, treatment and diagnosis. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are getting the highest standard of imaging care available.
EXPLORE OUR BREAST IMAGE CASE STUDIES*
At CureMetrix, we are designing our image analysis platform to empower physicians with the objective data they need to support patients as they make decisions with their healthcare team about their breast health. Our image analysis platform has the potential to quickly detect key regions of interest on a mammogram, and accurately quantify and classify the anomalies as suspicious or verifiably benign. We are developing a unique, data-driven “breast health score” that we believe, once validated, will allow physicians to confirm their evaluation of mammograms and to track their patients’ breast health over time.
CASE STUDY 1
Early Detection: in a blind review of prior images for this particular patient, the CureMetrix algorithm was able to detect and quantify an anomaly and show its evolution over time.
CASE STUDY 2
In this example of a dense breast, the CureMetrix algorithm was able to detect and mark an anomaly.
CASE STUDY 3
In this example of a small dense breast with breast implants, the CureMetrix Algorithm was able to detect and mark an anomaly and distinguish it from the background noise.
CASE STUDY 4
Early Detection: In a blind review of prior images for this patient, the CureMetrix algorithm was sensitive enough to detect this minute cluster of micro calcifications, specific enough to only mark the relevant anomalies, and show its evolution 3 years later.
CASE STUDY 5
Reduction of False Positives: In this example, the CureMetrix algorithm was sensitive enough to detect the anomalies but specific enough to correctly suggest that these anomalies were benign.